HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
Lr66JrJfsjJuGuuB